Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Podcasts

Listen to the latest hemonc news from international experts

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Systemic mastocytosis: current landscape, novel agents and COVID-19

Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with an associated hematological neoplasm (SM-AHN) or mast cell leukemia.

In this insightful podcast, Deepti Radia, MBBS, MRCPI, FRCPath, of Guy’s and St Thomas’ Hospital NHS Foundation Trust, London UK, firstly discusses the management of patients with systemic mastocytosis with associated hematological neoplasm. Dr Radia also details the current treatment options for this condition, as well as on-going clinical trials. Additionally, Dr Radia discusses the management of hematological oncology patients during the COVID-19 pandemic.
This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Date: 2nd June 2020

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.